Lupin Limited: Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in

Non-Dystrophic Myotonic Disorders

Zug, Switzerland, 8 January 2019: Lupin is pleased to announce that the European Commission (EC) has approved NaMuscla® (mexiletine) for the symptomatic treatment of